Every Form 4 that Bone Biologics Corp Warrants (BBLGW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BBLGW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BBLGW filings page.
Bone Biologics Corp director Robert E. Gagnon was granted non-employee stock options covering 113,896 Common Stock shares on September 28, 2026, at an exercise price of $0.50 per share. The report also lists directly held options for 10,483 shares at $5.28, 5,119 at $10.38, 2 at $25.44, and 1,335 at $25.44; these existing options are fully exercisable.
Bone Biologics Corp director Siddhesh Rajendra Angle received a grant of 113,896 non-employee stock options on September 28, 2026. The options have a $0.50 exercise price and expire September 28, 2036. The award was made under Bone Biologics Corporation's 2015 Equity Incentive Plan and described as exempt under Rule 16b-3.
Bone Biologics Corp director Phillip Terry Meikle II received non-employee stock options covering 113,896 common shares on September 28, 2026. They have a $0.50 exercise price, expire September 28, 2036, and generally vest in four equal quarterly installments, except as otherwise provided in the award notice. Other listed options cover 10,483 shares at $5.28, expiring June 4, 2035, and separate positions covering 4,698 and 2 shares at $11.28, expiring October 16, 2034; those options are fully exercisable as of the report date.
Bone Biologics Corp director Bruce Stroever received a grant of 113,896 non-employee stock options on September 28, 2026, with an exercise price of $0.50 per share and expiration on September 28, 2036. A separate direct option position covers 10,483 underlying shares at $5.28 per share and expires June 4, 2035.
Bone Biologics Corp reported an insider equity award for its Chief Financial Officer, Deina Walsh, on a Form 4. On January 8, 2026, she received an employee stock option covering 8,335 shares of common stock with an exercise price of $1.55 per share. According to the filing, this option was granted under the company’s 2015 Equity Incentive Plan and vests and becomes exercisable immediately, with an expiration date of January 8, 2036.
The filing also shows she holds another employee stock option for 4,510 shares at an exercise price of $5.82, which is fully vested and expires on January 15, 2027, as well as 313 shares of common stock held directly after the reported transactions.
Bone Biologics Corp reported an insider equity award for its Chief Executive Officer, Jeff Frelick. On January 8, 2026, he received an employee stock option grant covering 16,668 shares of common stock with an exercise price of $1.55 per share. The filing states that this option was granted under the company’s 2015 Equity Incentive Plan, is exempt under Rule 16b-3, and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.
After this grant, Frelick directly holds 16,668 of these new options, along with previously held, fully vested options on 9,019 shares at an exercise price of $5.82 and options on 8 shares at an exercise price of $73,800. He also directly owns 360 shares of Bone Biologics common stock.